| |
Lumbarspine (n=145) |
Total hip (n=193) |
At least one site (n=145) |
| |
OR (95% CI) |
p-value |
OR (95% CI) |
p-value |
OR (95% CI) |
p-value |
| Female |
15.9 (4.2-60.1) |
<0.001 |
6.9 (1.2-40.7) |
0.03 |
10.3 (3.3-32.6) |
<0.001 |
| Age (per 10 years) |
1.3 (0.6-3.0) |
0.49 |
1.9 (0.6-5.9) |
0.25 |
1.3 (0.6-2.7) |
0.51 |
| BMI (per kg/m2 increase) |
0.8 (0.7-1.0) |
0.021 |
0.8 (0.6-1.0) |
0.028 |
0.8 (0.7-1.0) |
0.017 |
| Current TDF use |
1.8 (0.5-5.9) |
0.36 |
_a |
_ |
1.4 (0.4-4.3) |
0.56 |
| Current PI use |
1.09 (0.3-4.3) |
0.90 |
_ |
_ |
_ |
_ |
| CD4 cell count<350 cells/μL |
3.0 (1.0-8.9) |
0.045 |
_ |
_ |
2.7 (1.0-7.5) |
0.048 |
OR: Odds Ratio; CI: Confidence Interval; BMI: Body Mass Index; ART: Antiretroviral Treatment; TDF: Tenofovir Disoproxyl Fumarate; PI: Protease Inhibitor
aFactors were not included in multivariate models (p-value>0.25 in univariate analysis; see Methods Section). |
